{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:47:46Z","timestamp":1792640866217,"version":"4.5.0"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>To summarize information on polymyositis; diagnosis, definitions, published data and opinions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Polymyositis originally referred to inflammatory muscle diseases presenting with muscle weakness and inflammatory cell infiltrates on muscle tissue visible by microscopy. Over time and with improved technology to immunophenotype infiltrating inflammatory cells and characterize muscle fibres, the meaning of polymyositis changed and became more specific. There is ongoing controversy over the term polymyositis, with proponents for a strict definition based on histopathological and immunohistochemical features on muscle biopsies whereas others advocate for a broader clinical and histopathological phenotype. Over the past decades, the discovery of several myositis-specific autoantibodies together with distinct histopathological features have enabled the identification of new subsets previously labelled as polymyositis notably the antisynthetase syndrome and the immune-mediated necrotizing myopathies thus reducing the number of patients classified as polymyositis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>There are still a small number of patients among the idiopathic inflammatory myopathies that can be classified as polymyositis as discussed in this review but the entity is now considered relatively rare.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000837","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T12:01:04Z","timestamp":1631102464000},"page":"537-543","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":35,"title":["Polymyositis: does it really exist as a distinct clinical subset?"],"prefix":"10.1097","volume":"33","author":[{"given":"Val\u00e9rie","family":"Leclair","sequence":"first","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine, Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden"},{"name":"Division of Rheumatology, Jewish General Hospital"},{"name":"Lady Davis Institute, Montreal, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Notarnicola","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Vencovsky","sequence":"additional","affiliation":[{"name":"Institute of Rheumatology, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid E.","family":"Lundberg","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,9,7]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1212\/WNL.61.3.316","article-title":"Polymyositis: an overdiagnosed entity","volume":"61","author":"van der Meulen","year":"2003","journal-title":"Neurology"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1001\/archneur.61.1.132","article-title":"Polymyositis: an ongoing discussion about a disease entity","volume":"61","author":"Bronner","year":"2004","journal-title":"Arch Neurol"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/mus.880050802","article-title":"Inflammatory myopathy: a review of etiologic and pathogenetic factors","volume":"5","author":"Whitaker","year":"1982","journal-title":"Muscle Nerve"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1001\/archneur.60.5.780","article-title":"History of dermatomyositis","volume":"60","author":"Levine","year":"2003","journal-title":"Arch Neurol"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(64)90792-5","article-title":"Some diseases of muscle","volume":"1","author":"Walton","year":"1964","journal-title":"Lancet"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/brain\/89.4.747","article-title":"Polymyositis: a survey of 89 cases with particular reference to treatment and prognosis","volume":"89","author":"Rose","year":"1966","journal-title":"Brain"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrrheum.2018.41","article-title":"Classification of myositis","volume":"14","author":"Lundberg","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11926-018-0726-4","article-title":"New myositis classification criteria-what we have learned since bohan and peter","volume":"20","author":"Leclair","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJM199111213252107","article-title":"Polymyositis, dermatomyositis and inclusion-body myositis","volume":"325","author":"Dalakas","year":"1991","journal-title":"N Engl J Med"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","article-title":"Polymyositis and dermatomyositis","volume":"362","author":"Dalakas","year":"2003","journal-title":"Lancet"},{"key":"R13-20250526","first-page":"668","article-title":"Classification criteria for polymyositis and dermatomyositis","volume":"22","author":"Tanimoto","year":"1995","journal-title":"J Rheumatol"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10\u201312 October 2003, Naarden, The Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscul Disord"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"(Pt 9)","key":"R16-20250526","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1093\/brain\/awv192","article-title":"Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis","volume":"138","author":"Mescam-Mancini","year":"2015","journal-title":"Brain"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1212\/WNL.0000000000001422","article-title":"Nuclear actin aggregation is a hallmark of antisynthetase syndrome-induced dysimmune myopathy","volume":"84","author":"Stenzel","year":"2015","journal-title":"Neurology"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1136\/annrheumdis-2019-216599","article-title":"Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis","volume":"79","author":"Pinal-Fernandez","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s41927-020-00125-8","article-title":"MicroRNA and mRNA profiling in the idiopathic inflammatory myopathies","volume":"4","author":"Parkes","year":"2020","journal-title":"BMC Rheumatol"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/annrheumdis-2012-201800","article-title":"Patients with non-Jo-1 antitRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients","volume":"73","author":"Aggarwal","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/acr2.11115","article-title":"A clinically and biologically based subclassification of the idiopathic inflammatory myopathies using machine learning","volume":"2","author":"Eng","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"102851","DOI":"10.1016\/j.autrev.2021.102851","article-title":"Histopathological features of systemic sclerosis-associated myopathy: a scoping review","volume":"20","author":"Lefebvre","year":"2021","journal-title":"Autoimmun Rev"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00401-021-02305-3","article-title":"Systemic sclerosis-associated myositis features minimal inflammation and characteristic capillary pathology","volume":"141","author":"Siegert","year":"2021","journal-title":"Acta Neuropathol"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00401-021-02335-x","article-title":"Capillary basement membrane reduplication in myositis patients with mild clinical features of systemic sclerosis supports the concept of 'scleromyositis\u2019","volume":"142","author":"Ellezam","year":"2021","journal-title":"Acta Neuropathol"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"e985","DOI":"10.1212\/WNL.0000000000006124","article-title":"Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer","volume":"91","author":"Touat","year":"2018","journal-title":"Neurology"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.nmd.2018.11.012","article-title":"Clinical spectrum of neuromuscular complications after immune checkpoint inhibition","volume":"29","author":"Puwanant","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"fcaa181","DOI":"10.1093\/braincomms\/fcaa181","article-title":"Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy","volume":"2","author":"Shelly","year":"2020","journal-title":"Brain Commun"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2018.09.033","article-title":"Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors","volume":"106","author":"Moreira","year":"2018","journal-title":"Eur J Cancer"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/art.41604","article-title":"Inflammatory myositis in cancer patients receiving immune checkpoint inhibitors","volume":"73","author":"Aldrich","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan","volume":"89","author":"Suzuki","year":"2017","journal-title":"Neurology"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"e558","DOI":"10.1212\/NXI.0000000000000558","article-title":"PD1 pathway in immune-mediated myopathies: pathogenesis of dysfunctional T cells revisited","volume":"6","author":"Knauss","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1093\/rheumatology\/key343","article-title":"The performance of the European League Against Rheumatism\/American College of Rheumatology idiopathic inflammatory myopathies classification criteria in an expert-defined 10\u200ayear incident cohort","volume":"58","author":"Parker","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3349\/ymj.2021.62.5.424","article-title":"Comparison of the 2017\u200aEULAR\/ACR criteria with clinicoserologic criteria for the classification of idiopathic inflammatory myopathies in Korean patients","volume":"62","author":"Chung","year":"2021","journal-title":"Yonsei Med J"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1093\/rheumatology\/keaa801","article-title":"Polymyositis: is there anything left? A retrospective diagnostic review from a tertiary myositis centre","volume":"60","author":"Loarce-Martos","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3389\/fimmu.2019.00444","article-title":"Diagnostic utility of separate anti-Ro60 and anti-Ro52\/TRIM21 antibody detection in autoimmune diseases","volume":"10","author":"Robbins","year":"2019","journal-title":"Front Immunol"},{"key":"R36-20250526","article-title":"Myositis specific antibodies are associated with isolated anti-Ro-52 associated interstitial lung disease","author":"Shao","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"105920","DOI":"10.1016\/j.rmed.2020.105920","article-title":"Clinical characteristics of patients with anti-EJ antisynthetase syndrome associated interstitial lung disease and literature review","volume":"165","author":"Liu","year":"2020","journal-title":"Respir Med"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/14397595.2017.1317377","article-title":"Anti-SS-A\/Ro antibody positivity as a risk factor for relapse in patients with polymyositis\/dermatomyositis","volume":"28","author":"Tatebe","year":"2018","journal-title":"Mod Rheumatol"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"e1416","DOI":"10.1212\/WNL.0000000000007188","article-title":"Muscular and extramuscular features of myositis patients with anti-U1-RNP autoantibodies","volume":"92","author":"Casal-Dominguez","year":"2019","journal-title":"Neurology"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/MD.0000000000000222","article-title":"Redefining dermatomyositis: a description of new diagnostic criteria that differentiate pure dermatomyositis from overlap myositis with dermatomyositis features","volume":"93","author":"Troyanov","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/WCO.0000000000000376","article-title":"Advances in serological diagnostics of inflammatory myopathies","volume":"29","author":"Benveniste","year":"2016","journal-title":"Curr Opin Neurol"},{"key":"R42-20250526","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001357","article-title":"Recognising the spectrum of scleromyositis: HEp-2 ANA patterns allow identification of a novel clinical subset with anti-SMN autoantibodies","volume":"6","author":"Landon-Cardinal","year":"2020","journal-title":"RMD Open"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/art.30349","article-title":"Autoantibodies to survival of motor neuron complex in patients with polymyositis: immunoprecipitation of D, E, F, and G proteins without other components of small nuclear ribonucleoproteins","volume":"63","author":"Satoh","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1172\/JCI81031","article-title":"Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies","volume":"125","author":"Albrecht","year":"2015","journal-title":"J Clin Invest"},{"key":"R45-20250526","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/rheumatology\/kez406","article-title":"Identification of a novel autoantigen eukaryotic initiation factor 3 associated with polymyositis","volume":"59","author":"Betteridge","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jocn.2019.11.029","article-title":"Differential and quantitative neuroimaging characteristics of inclusion body myositis","volume":"72","author":"Furuta","year":"2020","journal-title":"J Clin Neurosci"},{"key":"R47-20250526","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1136\/annrheumdis-2018-214644","article-title":"[18F]Florbetapir positron emission tomography: identification of muscle amyloid in inclusion body myositis and differentiation from polymyositis","volume":"78","author":"Lilleker","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R48-20250526","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/mus.26875","article-title":"Ultrasound can differentiate inclusion body myositis from disease mimics","volume":"61","author":"Leeuwenberg","year":"2020","journal-title":"Muscle Nerve"},{"key":"R49-20250526","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.ultrasmedbio.2021.04.019","article-title":"Musculoskeletal ultrasound in inclusion body myositis: a comparative study with magnetic resonance imaging","volume":"47","author":"Guimaraes","year":"2021","journal-title":"Ultrasound Med Biol"},{"key":"R50-20250526","first-page":"289","article-title":"Inflammatory myopathies: update on diagnosis, pathogenesis and therapies, and COVID-19-related implications","volume":"39","author":"Dalakas","year":"2020","journal-title":"Acta Myol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000837","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T22:00:35Z","timestamp":1748296835000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,7]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000837","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,7]]}}}